Affimed (AFMD) –
-
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
-
Affimed Therapeutics (AFMD) PT Lowered to $20 at Jefferies
-
Affimed Therapeutics (AFMD) PT Raised to $5 at Stifel
-
Affimed Therapeutics (AFMD) PT Lowered to $25 at Wells Fargo
-
Affimed Therapeutics (AFMD) PT Raised to $10 at H.C. Wainwright
-
Form 6-K Affimed N.V. For: Mar 28
-
Form 20-F Affimed N.V. For: Dec 31
-
Affimed Reports 2023 Financial Results and Operational Progress
-
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
-
Form 6-K Affimed N.V. For: Mar 11
-
Form 6-K Affimed N.V. For: Mar 06
-
Affimed (AFMD) Announces 1:10 Reverse Share Split
-
Affimed Announces 1-for-10 Reverse Stock Split
-
Form SC 13G/A Affimed N.V. Filed by: Ridgeback Capital Investments L.P.
-
Form SC 13G/A Affimed N.V. Filed by: 683 Capital Management, LLC
-
Form 6-K Affimed N.V. For: Jan 08
-
Affimed (AFMD) Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
-
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
-
Form 6-K Affimed N.V. For: Jan 08
-
Affimed (AFMD) Announces CEO Resignation, Cuts 50% Staff
-
Affimed Announces Leadership Change and Organizational Restructuring
-
Affimed (AFMD) Sells AbCheck
-
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
-
Midday movers: Macy’s, Broadcom, Eli Lilly and more
-
Form 6-K Affimed N.V. For: Dec 11
-
Affimed (AFMD) AFM24 with atezolizumab study showed encouraging signals of clinical activity
-
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
-
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (B
-
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
-
Form 6-K Affimed N.V. For: Nov 30
-
Affimed Therapeutics (AFMD) PT Lowered to $3 at Wells Fargo
-
Form 6-K Affimed N.V. For: Nov 14
-
Affimed (AFMD) Tops Q3 EPS by 2c
-
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
-
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
-
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
-
Affimed (AFMD) Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types
-
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Im
-
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
-
Affimed to Participate in Upcoming Investor Conferences
-
Form 6-K Affimed N.V. For: Oct 04
-
Affimed Announces Listing Transfer to Nasdaq Capital Markets
-
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy o
-
Affimed to Present at the Cantor Global Healthcare Conference 2023
-
Affimed (AFMD) Granted FDA Fast Track Designation for AFM13 in Combination with AlloNK
-
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
-
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
-
Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability
-
Affimed Therapeutics (AFMD) PT Lowered to $6 at Truist Securities
-
Affimed Therapeutics (AFMD) PT Lowered to $4 at Wells Fargo
Back to AFMD Stock Lookup
